Published in Medical Letter on the CDC and FDA, April 2nd, 2006
Under the alliance, PacificGMP will assist Novavax in developing the capability of manufacturing large quantities of vaccine to accommodate the surge capacity that must be met in the event of a pandemic outbreak of influenza.
PacificGMP will utilize disposable bioprocessing technology to manufacture and produce Novavax's VLP avian flu vaccine. Use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.